Hello, everyone, and how are you today? We hope the weekend was refreshing and relaxing. Now, though, that usual routine of meetings and deadlines is about to resume. It may be mid-summer, but the world is still spinning, which means there is much to do. To help us get started, yes, we are brewing a nice cup of stimulation and, as always, invite you to join us. Meanwhile, here are some tidbits to spur the brain cells. Hope your day goes well and you accomplish much. Catch you soon...
Elan To Spin Off Research Unit (Reuters)
Acorda Therapeutics Says Low-Dose Ampyra Was Not Effective (Dow Jones)
Express Scripts To Divest Some Businesses (Pharmaceutical Processing)
UK's NICE Wants More Info On Roche Melanoma Pill (Reuters)
Sun Pharma To Take Taro Private (Globes)
FDA OKs Lucentis For Diabetic Eye Disorder (Wall Street Journal)
Novo Nordisk May Drop Hemophilia Drug (Reuters)
J&J Ethicon Unit Recalls Surgical Staplers (Mass Device)
EMA Wants CRO & Sponsor Input On Publishing Trial Data (Outsourcing Pharma)
Rising Prices For Some Dermatology Creams Cause A Mystery (New York Times)
Icahn Accuses Forest Of Hiding Poison Pill Agreement (Reuters)
Sanofi Reorganization Enrages The French (Bloomberg News)
EDITOR'S NOTE: Please check this post for updates during the day
1 Comment
Regards,
Montgomery Burns, Lab Manager